Year-end Sale % OFF 
Abstract
The liver function was studied in 15 patients before and during treatment with cefuroxime. Four elderly patients had a prolonged half-life of galactose at admission but they all showed declining values during the cefuroxime treatment. Only in one patient did the galactose half-life increase during treatment (from 14 to 25 min.). This patient was an old diabetic who also had prostatic cancer. Cefuroxime treatment seems to be well tolerated also in patients with signs of impaired metabolic liver function at start of treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
